The Bone Cancer Research Trust has made significant progress in the fight against primary bone cancer since their inception in 2006; from developing pioneering treatment methods to creating training tools for healthcare professionals in order to aid earlier diagnosis. Read on to keep up to date with our latest research news.
Our commitment to research
A major part of our strategy is our commitment to research. Research is key to saving lives and finding a cure. To date, researchers have not had the necessary funding and career pathways in place to enable research or specialism in the field of primary bone cancer. It is crucial we support this research and in order to do so we have committed to funding over £2.8 million over the next 5 years.
To kick-start this, we have committed to funding two new research projects, totalling a spend of £620,000. Furthermore, we have announced a third grant in collaboration with our friends at the Ewing’s Sarcoma Research Trust.
Read more on our commitment to research funding and our three new grant calls on our News page, by clicking here.
Ewing Sarcoma Travel Scholarship 2017/2018
Are you based in Europe and carrying out research or working with patients with Ewing sarcoma? Would you like the opportunity to work in another lab or hospital anywhere in the world?
The EURO EWING Consortium (EEC) is running a call for applications for one or more travel scholarships. Read more on the scholarship and find details on how to apply by clicking here.
Strictly Research 2017
This year, the Bone Cancer Conference 2017 saw the return of ‘Strictly Research'. This interactive session saw our research grant applicants pitch their projects to a live audience and expert judging panel, leaving the funding decision in the hands of our conference attendees.
Read more on how the Strictly Research session took place and the winning projects, by clicking here.
The launch of our 2017-2022 Strategy
During our Bone Cancer Conference 2017, we launched out new straegy 'The Biggest Ever Commitment to Primary Bone Cancer'. This 5 year strategy outlines our aims and priorities from 2017-2022.
Read the full strategy and learn more on our commitments by clicking here.
Research Funding: Aiming to prevent the growth and spread of osteosarcoma
Following successful research projects funded by the Bone Cancer Research Trust back in 2007 and 2009, Professor Grigoriadis has been able to confirm the expression of a well-known cell membrane receptor, known as FGFR in osteosarcoma. He is now investigating the exact mechanism in closer detail; determining if, and how, this molecule can be targeted in order to develop a new treatment option for patients.
Read more on this research project here.
Introducing our new Infrastructure Grants
This month, the Bone Cancer Research Trust released our new area of grant funding which aim to facilitate the collection of patient samples to be used for research. These are known as our 'Infrastructure Grants'.
Read more and hear from our Head of Research and Information, Dr Zoe Davison, as she explains how our new grants will work and how patient samples can have great benefit to research, by clicking here.
How Can Junior Doctors Improve Their Knowledge of Sarcoma?
In the United Kingdom, there are currently no designated modules on the undergraduate medical curriculum on sarcomas, and fewer than 20 designated centres treating sarcoma patients. Dr Charlie Zhou, a junior doctor who took part in our National Sarcoma Awareness Project, spoke to the Bone Cancer Research Trust about his placement at a specialised sarcoma centre and what he learnt from his time there.
You can read his interview in full here.
Bone Cancer Research Trust at the British Sarcoma Group (BSG) Conference
The annual BSG conference is a unique opportunity to meet and learn more from specialist clinicians, nurses and other professionals all working to research and/or treat sarcoma. The busy programme included reviews of recent sarcoma clinical trials and research as well as updates to national treatment guidelines. The Bone Cancer Research Trust had a stand jam packed with the information we provide and were on hand to answer questions and get to know the conference delegates.
Could this be the first ever clinical biomarker for chondrosarcoma?
In February 2017, the Bone Cancer Research Trust funded the first of the years research grants to Professor Adrienne Flanagan, allowing her to carry out her research into chondrosarcoma for the next 3 years.
Professor Flanagan has identified a promising biomarker, in the form of a mutation to a gene known as IDH1; which are present in approximately 50% of chondrosarcomas. This project will look at expanding Professor Flanagan's knowledge and determine if measuring the levels of the IDH1 biomarker in a diagnostic biopsy and in blood tests can predict the grade of a patient’s chondrosarcoma more accurately than just looking down a microscope.
You can read more in-depth summary of this research project here.
What we learnt at this years Euro-Ewing Consortium Meeting
The Euro Ewing Consortium group, who meet twice a year, aim to increase the number of patients with access to clinical trials while sharing their knowledge on an international level. This months Euro-Ewing Consortium (EEC) meeting was held in London and brought together partners from around Europe to work together to improve survival rates for Ewing sarcoma patients and develop further treatment options.
To learn more on our highlights from this 2 day meeting, or to find out how you can get involved with the EEC, please click here to read more.